Dale Bryant is a senior Post-doctoral Research Associate in the Kinsler Lab. He completed his PhD in 2014 where he was working on neural stem cells and histone deacetylases in the Department of Medical and Molecular Genetics, King’s College London and Pfizer, Cambridge. He then completed postdoctoral positions on cell and animal models of genetic diseases involving cerebellar ataxia and hearing loss at Great Ormond Street Institute of Child Health, University College London. Dale joined the Kinsler lab in 2019 to focus on precision therapies for Congenital Melanocytic Naevi.

Displaying 1 - 7 of 7
Last updated : 12 August 2026 03:41

RNA therapy for oncogenic NRAS-driven naevi induces apoptosis

Authors (18)
  • Dale Bryant
  • Sara Barberan-Martin
  • Ruhina Maeshima
  • Ignacio Del Valle Torres
  • Mohammad Rabii
  • William Baird
  • [...]
  • Davide Zecchin
  • Alan Pittman
  • Satyamaanasa Polubothu
  • Stephen Hart
  • Veronica Kinsler

Inherited duplications of PPP2R3B predispose to nevi and melanoma via a C21orf91-driven proliferative phenotype

Authors (46)
  • Satyamaanasa Polubothu
  • Davide Zecchin
  • Lara Al-Olabi
  • Daniël A Lionarons
  • Mark Harland
  • Stuart Horswell
  • [...]
  • Gudrun E Moore
  • Wei-Li Di
  • Julia Newton-Bishop
  • Julian Downward
  • Veronica Kinsler